US Patent 8449885 Anti-VEGF antibodies
Patent 8449885 was granted and assigned to Genentech on May, 2013 by the United States Patent and Trademark Office.
All edits
Edits on 30 Nov, 2023
Golden AI
Edits made to:
Article (+451 characters)
Article
Patent abstract
The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.
Edits on 7 Jun, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 17 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08449885 Anti-VEGF antibodies US Patent 8449885 Anti-VEGF antibodies
Infobox
Patent Number
0844988500
Patent Number
844988500
Edits on 27 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
084498850
Date of Patent
May 28, 2013
0Patent Application Number
128178270
Date Filed
June 17, 2010
0Patent Primary Examiner
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
084498850
Date of Patent
May 28, 2013
0Patent Application Number
128178270
Date Filed
June 17, 2010
0Patent Primary Examiner
Edits on 16 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08449885 Anti-VEGF antibodies
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08449885
Date of patent
May 28, 2013
Patent application number
12817827
Date Filed
June 17, 2010
Patent primary examiner
Find more entities like US Patent 8449885 Anti-VEGF antibodies
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
